EPGA: AWeb-based information system for translational pharmacogenomics

PLoS ONE

Volumn 11, Issue 9, 2016, Pages

  Lakiotaki, Kleanthi ^a   Kartsaki, Evgenia ^a   Kanterakis, Alexandros ^a   Katsila, Theodora ^b   Patrinos, George P ^b   Potamias, George ^a  

^a INSTITUTE OF COMPUTER SCIENCE   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DRUG METABOLISM; GENE; GENE EXPRESSION PROFILING; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; INTERNET; MEDICAL INFORMATION SYSTEM; PHARMACOGENOMICS; PHENOTYPE; PRACTICE GUIDELINE; STATISTICS; UGT1A5 GENE; INFORMATION SYSTEM; PHARMACOGENETICS; THEORETICAL MODEL;

INFORMATION SYSTEMS; INTERNET; MODELS, THEORETICAL; PHARMACOGENETICS;

EID: 84992391779     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0162801     Document Type: Article

References (40)

1. Younesi E, Hofmann-Apitius M. From integrative disease modeling to predictive, preventive, personalized and participatory (P4) medicine. EPMA J. BioMed Central Ltd; 2013; 4: 23. doi:10.1186/1878-5085-4-23PMID: 24195840.
2. Lippert C, Listgarten J, Davidson RI, Baxter S, Poon H, Poong H, et al. An exhaustive epistatic SNP association analysis on expandedWellcome Trust data. Sci Rep. 2013; 3: 1099. doi:10.1038/srep01099 PMID: 23346356.
3. Potamias G, Lakiotaki K, Katsila T, Lee MTM, Topouzis S, Cooper DN, et al. Deciphering next-generation pharmacogenomics: An information technology perspective. Open Biol. 2014; 4. doi:10.1098/rsob.140071.
4. Sebelius K, Frieden TR, Sondik EJ. Health, United States, 2009 with Special Feature on Medical Technology. National Center for Health Statistics. 2009.
5. Kampourakis K, Vayena E, Mitropoulou C, van Schaik RH, Cooper DN, Borg J, et al. Key challenges for next-generation pharmacogenomics. EMBO Rep. 2014; 15: 472-476. doi:10.1002/embr.201438641 PMID: 24723683.
6. Motsinger-Reif AA, Jorgenson E, Relling MV, Kroetz DL, Weinshilboum R, Cox NJ, et al. Genomewide association studies in pharmacogenomics: successes and lessons. Pharmacogenet Genomics. 2013; 23: 383-94. doi:10.1097/FPC.0b013e32833d7b45 PMID: 20639796.
7. Altman RB, Whirl-Carrillo M, Klein TE. Challenges in the pharmacogenomic annotation of whole genomes. Clin Pharmacol Ther. 2013; 94: 211-3. doi:10.1038/clpt.2013.111 PMID: 23708745.
8. Ritchie MD. The success of pharmacogenomics in moving genetic association studies from bench to bedside: study design and implementation of precision medicine in the post-GWAS era. Hum Genet. 2012; 131: 1615-26. doi:10.1007/s00439-012-1221-z PMID: 22923055.
9. Lee JW, Aminkeng F, Bhavsar A. P, Shaw K, Carleton BC, Hayden MR, et al. The emerging era of pharmacogenomics: Current successes, future potential, and challenges. Clin Genet. 2014; 86: 21-28. doi:10.1111/cge.12392 PMID: 24684508.
10. Squassina A, Manchia M, Manolopoulos VG, Artac M, Lappa-Manakou C, Karkabouna S, et al. Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice. Pharmacogenomics. 2010; 11: 1149-1167. doi:10.2217/pgs.10.97 PMID: 20712531.
11. Harper AR, Topol EJ. Pharmacogenomics in clinical practice and drug development. Nat Biotechnol. Nature Publishing Group; 2012; 30: 1117-24. doi:10.1038/nbt.2424 PMID: 23138311.
12. Lakiotaki K, Patrinos GP, Potamias G. InformationTechnology meets Pharmacogenomics: Design Specifications of an Integrated Personalized Pharmacogenomics Information System. IEEE-EMBS Int Conf Biomed Heal Informatics. 2014; 13-16.
13. Papadopoulos P, Viennas E, Gkantouna V, Pavlidis C, Bartsakoulia M, Ioannou Z-M, et al. Developments in FINDbaseworldwide database for clinically relevant genomic variation allele frequencies. Nucleic Acids Res. 2014; 42: D1020- D6. doi:10.1093/nar/gkt1125 PMID: 24234438.
14. Cheng R, Leung RK-K, Chen Y, Pan Y, Tong Y, Li Z, et al. Virtual Pharmacist: A Platformfor Pharmacogenomics. PLoS One. Public Library of Science; 2015; 10. doi:10.1371/journal.pone.0141105.
15. Sim SC, Altman RB, Ingelman-Sundberg M. Databases in the area of pharmacogenetics. Human Mutation. 2011. pp. 526-531. doi:10.1002/humu.21454 PMID: 21309040.
16. Shuldiner AR, Relling M V, Peterson JF, Hicks JK, Freimuth RR, SadeeW, et al. The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Overcoming Challenges of Real- World Implementation. Clin Pharmacol Ther. 2013; 94: 207-210. doi:10.1038/clpt.2013.59 PMID: 23588301.
17. Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee A H, Mulder H, et al. Pharmacogenetics: from bench to byte-An update of guidelines. Clin Pharmacol Ther. Nature Publishing Group; 2011; 89: 662-73. doi:10.1038/clpt.2011.34 PMID: 21412232.
18. Karnes JH, Van Driest S, Bowton EA, Weeke PE, Mosley JD, Peterson JF, et al. Using systems approaches to address challenges for clinical implementation of pharmacogenomics. Wiley InterdisciplinaryReviews: Systems Biology and Medicine. 2014. pp. 125-135. doi:10.1002/wsbm.1255.
19. Xie L, Ge X, Tan H, Xie L, Zhang Y, Hart T, et al. Towards Structural Systems Pharmacology to Study Complex Diseases and Personalized Medicine. PLoS Comput Biol. 2014; 10. doi:10.1371/journal.pcbi.1003554.
20. Mette L, Mitropoulos K, Vozikis A, Patrinos GP. Pharmacogenomics and public health: implementing "populationalized" medicine. Pharmacogenomics. 2012; 13: 803-813. doi:10.2217/pgs.12.52 PMID: 22594512.
21. Mitropoulou C, Mai Y, Van Schaik RH, Vozikis A, Patrinos GP. Stakeholder analysis in pharmacogenomics and genomic medicine in Greece. Public Health Genomics. 2014; 17: 280-286. doi:10.1159/000365896 PMID: 25228172.
22. Katsila T, Patrinos GP. Whole genome sequencing in pharmacogenomics. Front Pharmacol. 2015; 6: 1-3. doi:10.3389/fphar.2015.00061 PMID: 25805991.
23. Salleh MZ, Teh LK, Lee LS, Ismet RI, Patowary A, Joshi K, et al. Systematic Pharmacogenomics Analysis of a Malay Whole Genome: Proof of Concept for Personalized Medicine. PLoS One. 2013; 8. doi:10.1371/journal.pone.0071554.
24. Relling MV, Klein TE. CPIC: Clinical Pharmacogenetics Implementation Consortiumof the Pharmacogenomics Research Network. Clin Pharmacol Ther. Nature Publishing Group; 2011; 89: 464-7. doi:10.1038/clpt.2010.279 PMID: 21270786.
25. Giacomini KM, Brett CM, Altman RB, Benowitz NL, Dolan ME, Flockhart D a, et al. The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther. 2007; 81: 328-45. doi:10.1038/sj.clpt.6100087 PMID: 17339863.
26. Whirl-Carrillo M, McDonagh EM, Hebert JML, Gong KS, Thorn CF, Altman RB, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012; 92: 414-417. doi:10.1038/clpt.2012.96.Pharmacogenomics PMID: 22992668.
27. Robarge JD, Li L, Desta Z, Nguyen A, Flockhart DA. The Star-Allele Nomenclature: Retooling for Translational Genomics. Clin Pharmacol Ther. 2007; 82: 244-248. doi:10.1038/sj.clpt.6100284PMID: 17700589.
28. Ma Q, Lu A. Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol Rev. 2011; 63: 437-459. doi:10.1124/pr.110.003533.nome-disease PMID: 21436344.
29. Crews KR, Hicks JK, Pui C-H, RellingM V, Evans WE. Pharmacogenomics and Individualized Medicine: Translating Science Into Practice. Clin Pharmacol Ther. 2012; 92: 467-475. doi:10.1038/clpt.2012.120 PMID: 22948889.
30. Zhang H, Meltzer P, Davis S. RCircos: An R package for Circos 2D track plots. BMC Bioinformatics. 2013; 14: 244. doi:10.1186/1471-2105-14-244 PMID: 23937229.
31. Project 1000 Genomes, Durbin RM, Abecasis GR, Altshuler DL, Auton A, Brooks LD, et al. A map of human genome variation from population-scale sequencing. Nature. 2010; 467: 1061-1073. doi:10.1038/nature09534 PMID: 20981092.
32. Pareek CS, Smoczynski R, Tretyn A. Sequencing technologies and genome sequencing. J Appl Genet. Berlin/Heidelberg: Springer-Verlag; 2011; 52: 413-435. doi:10.1007/s13353-011-0057-x PMID: 21698376.
33. Dalabira E, Viennas E, Daki E, Komianou A, Bartsakoulia M, Poulas K, et al. DruGeVar: An Online Resource Triangulating Drugs with Genes and Genomic Biomarkers for Clinical Pharmacogenomics. Public Health Genomics. 2014; 17: 265-271. doi:10.1159/000365895 PMID: 25228099.
34. Sim SC, Ingelman-Sundberg M. The Human Cytochrome P450 (CYP) Allele Nomenclature website: A peer-reviewed database of CYP variants and their associated effects. Hum Genomics. 2010; 4: 278-81. Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3525213&tool=pmcentrez&rendertype=abstractPMID: 20511141.
35. Mark Farmen William Koh SLC. Translation of Drug Metabolic Enzyme and Transporter (DMET) Genetic Variants into Star Allele Notation using SAS. PharmaSUGConference, Portland, Oregon, May 31-June 3, 2009, Paper PR03-2009. 2009.
36. Mizzi C, Peters B, Mitropoulou C, Mitropoulos K, Katsila T, Agarwal MR, et al. Personalized pharmacogenomics profiling using whole-genome sequencing. Pharmacogenomics. 2014; 15: 1223-34. Available: http://www.ncbi.nlm.nih.gov/pubmed/25141897doi:10.2217/pgs.14.102 PMID: 25141897.
37. Squassina A, Manchia M, Borg J, Congiu D, Costa M, Georgitsi M, et al. Evidence for association of an ACCN1 gene variant with response to lithium treatment in Sardinian patients with bipolar disorder. Pharmacogenomics. 2011; 12: 1559-69. doi:10.2217/pgs.11.102 PMID: 21961650.
38. Patrinos GP, Cooper DN, van Mulligen E, Gkantouna V, Tzimas G, Tatum Z, et al. Microattribution and nanopublication as means to incentivize the placement of human genome variation data into the public domain.Hum Mutat. 2012; 33: 1503-1512. doi:10.1002/humu.22144 PMID: 22736453.
39. Giardine B, Borg J, Higgs DR, Peterson KR, Philipsen S, Maglott D, et al. Systematic documentation and analysis of human genetic variation in hemoglobinopathies using the microattribution approach. Nat Genet. 2011; 43: 295-301. doi:10.1038/ng.785 PMID: 21423179.
40. Brookes AJ, Robinson PN. Human genotype-phenotype databases: Aims, challenges and opportunities. Nat Rev Genet. Nature Publishing Group; 2015; 16: 702-715. doi:10.1038/nrg3932 PMID: 26553330.